Miss Angela Casbard - Porth Ymchwil - Ffurfwedd Safonol Converis

Ewch i'r Pennawd Ewch i'r Dudalen Lywio Ewch i'r Cynnwys Ewch i'r Troednodyn

Rhestr o bobl » Miss Angela Casbard

Miss Angela Casbard

Prosiectau fel Prif Ymchwiliwr

null

null

1 o 2

null

null

A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy - FURVA CRUK - Cyllidwr:Cancer Research UK (01.10.2014 - 30.09.2017)

A randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma - VIM - Cyllidwr:Cancer Research UK, - Cyllidwr:University of Leicester (01.11.2013 - 31.12.2020)

A phase 1b/randomised placebo controlled phase II trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor - FAKTION CRUK - Cyllidwr:Cancer Research UK (01.10.2013 - 31.10.2019)

A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy - FURVA AZ - Cyllidwr:AstraZeneca UK Ltd (01.10.2014 - 30.09.2020)

Phase II evaluation of cediranib in combination with paclitaxel of olaparib in advanced/metastatic endometrial carcinoma (COPELIA) - Cyllidwr:AstraZeneca UK Ltd (01.10.2017 - 30.06.2022)

Prosiectau fel Cyd-Ymchwiliwr

null

null

1 o 2

null

null

A randomised phase II trial of carboplation and gemcitabane +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin - TOUCAN - Cyllidwr:AstraZeneca UK Ltd, - Cyllidwr:AstraZeneca UK Ltd (19.10.2009 - 30.09.2020)

TOTEM: A phase I/II single-arm trial to evaluate the combination of cisplatin and gemcitabine with the mTOR inhibitor temsirolimus for first-line treatment of patients with advanced transitional cell carcinoma of the urothelium - Cyllidwr:Pfizer Ltd (07.11.2011 - 30.09.2019)

SKOPOS - Cyllidwr:Velindre NHS Trust (01.01.2013 - 31.12.2016)

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin in the treatment of Cancer Associated Thrombosis (ALICAT) - Cyllidwr:National Institute for Health Research (01.03.2013 - 28.02.2015)

Folfera Trial - Cyllidwr:AstraZeneca UK Ltd, - Cyllidwr:AstraZeneca UK Ltd (01.09.2009 - 30.09.2020)

Diweddarwyd y tro diwethaf ar 2021-11-01 am 22:06